UnitedHealthcare Pharmacy
Clinical Pharmacy Programs
Program Number 2025 P 1280-7
Program Prior Authorization/Notification
Medication Inbrija® (levodopa inhalation powder)
P&T Approval Date 5/2019, 5/2020, 5/2021, 5/2022, 5/2023, 2/2024, 2/2025
Effective Date 5/1/2025
1. Background:
Inbrija® (levodopa inhalation powder) is an aromatic amino acid indicated for the intermittent
treatment of OFF episodes in patients with Parkinson’s disease treated with
carbidopa/levodopa.
Inbrija should only be administered with the Inbrija inhaler.
Coverage will be provided for members who meet the following criteria.
2. Coverage Criteriaa:
A. Initial Authorization
1. Inbrija will be approved based on all of the following criteria:
a. Diagnosis of Parkinson’s disease
- AND-
b. Used as intermittent treatment for OFF episodes
- AND-
c. Patient is currently on and will continue to receive treatment with a
carbidopa/levodopa-containing medication
Authorization will be issued for 12 months.
B. Reauthorization
1. Inbrija will be approved based on the following criteria:
a. Documentation of positive clinical response to Inbrija therapy
- AND-
b. Patient will continue to receive treatment with a carbidopa/levodopa-containing
medication
© 2025 UnitedHealthcare Services, Inc.
1
Authorization will be issued for 12 months.
a State mandates may apply. Any federal regulatory requirements and the member specific
benefit plan coverage may also impact coverage criteria. Other policies and utilization
management programs may apply.
3. Additional Clinical Rules:
• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-
authorization based solely on previous claim/medication history, diagnosis codes (ICD-
10) and/or claim logic. Use of automated approval and re-approval processes varies by
program and/or therapeutic class.
• Supply limits and/or Step Therapy may be in place.
4. References:
1. Inbrija [package insert]. Ardsley, NY: Acorda Therapeutics, Inc.; December 2022.
Program Prior Authorization/Notification - Inbrija® (levodopa inhalation
powder)
Change Control
5/2019 New program
5/2020 Annual review. Updated reference.
5/2021 Annual review. Updated reference.
5/2022 Annual review with no change to clinical criteria.
5/2023 Annual review with no change to clinical criteria. Added state mandate
footnote. Updated reference.
2/2024 Revised initial authorization to 12 months.
2/2025 Annual review with no change to clinical criteria.
© 2025 UnitedHealthcare Services, Inc.
2